AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of fabry disease. The company is also developing AVR-RD-02 for the treatment of type 1 gaucher disease; AVR-RD-03 for the treatment of pompe disease; and AVR-RD-04 for the treatment of cystinosis. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-914-8420
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees34
OptionableNot Optionable
Avrobio (NASDAQ:AVRO) Frequently Asked Questions
What is Avrobio's stock symbol?
Avrobio trades on the NASDAQ under the ticker symbol "AVRO."
How were Avrobio's earnings last quarter?
Avrobio Inc (NASDAQ:AVRO) issued its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.91) by $0.42. View Avrobio's Earnings History.
When is Avrobio's next earnings date?
What price target have analysts set for AVRO?
7 brokers have issued twelve-month target prices for Avrobio's stock. Their predictions range from $19.00 to $40.00. On average, they anticipate Avrobio's stock price to reach $35.40 in the next year. This suggests a possible upside of 165.0% from the stock's current price. View Analyst Price Targets for Avrobio.
What is the consensus analysts' recommendation for Avrobio?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avrobio.
What are Wall Street analysts saying about Avrobio stock?
Here are some recent quotes from research analysts about Avrobio stock:
- 1. According to Zacks Investment Research, "Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States. " (1/15/2019)
- 2. HC Wainwright analysts commented, "Our $40 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF analysis, which is based on: beta of 1.15, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.5%, and tax rate of 15% beginning in FY 2028. Our price target reflects uncertainties stemming from the clinical update from the Fabry program (AVR-RD-01), resulting in: (1) a push out of our launch estimate into 2H-2022, vs. prior 2H-2021; and (2) lower Fabry POS of 25% from 30%." (1/15/2019)
Has Avrobio been receiving favorable news coverage?
Headlines about AVRO stock have been trending very positive recently, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avrobio earned a news impact score of 3.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are some of Avrobio's key competitors?
Some companies that are related to Avrobio include Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Momenta Pharmaceuticals (MNTA), Sangamo Therapeutics (SGMO), Iovance Biotherapeutics (IOVA), Orchard Therapeutics (ORTX), Rubius Therapeutics (RUBY), Audentes Therapeutics (BOLD), Fate Therapeutics (FATE), BioCryst Pharmaceuticals (BCRX), Solid Biosciences (SLDB), Coherus Biosciences (CHRS), Novavax (NVAX), Vericel (VCEL) and Acorda Therapeutics (ACOR).
Who are Avrobio's key executives?
Avrobio's management team includes the folowing people:
- Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 52)
- Ms. Katina Dorton, Chief Financial Officer (Age 60)
- Dr. Nerissa Kreher, Chief Medical Officer (Age 45)
- Mr. Jeffrey Medin Ph.D., Scientific Founder
- Dr. Kim Warren, Head of Operations
When did Avrobio IPO?
(AVRO) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.
When did Avrobio's lock-up period expire?
Avrobio's lock-up period expired on Tuesday, December 18th. Avrobio had issued 5,247,958 shares in its IPO on June 21st. The total size of the offering was $99,711,202 based on an initial share price of $19.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.
How do I buy shares of Avrobio?
Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avrobio's stock price today?
One share of AVRO stock can currently be purchased for approximately $13.36.
How big of a company is Avrobio?
Avrobio has a market capitalization of $320.05 million. Avrobio employs 34 workers across the globe.
What is Avrobio's official website?
How can I contact Avrobio?
Avrobio's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]
MarketBeat Community Rating for Avrobio (NASDAQ AVRO)
MarketBeat's community ratings are surveys of what our community members think about Avrobio and other stocks. Vote "Outperform" if you believe AVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
